Technology Bundle ID
TAB-2698

Nucleic Acid Detection of the Fungal Pathogen Histoplasma capsulatum from Clinical and Environmental Samples

Linked ID
E-313-2013-0
Lead Inventors
Millie Schafer (CDC)
Co-Inventors
Thomas Reid (CDC)
Development Stages
Development Status
In vitro data available
ICs
This invention relates to detecting Histoplasma capsulatum by PCR using oligonucleotide probes specific for the fungus. Histoplasmosis is a mycotic infection of varying severity, usually localized in the lungs. Caused by H. capsulatum, infections are usually symptomatic but can develop into chronic disease, especially in immunocompromised individuals.

Test samples may originate from the environment (soil, for example), where H. capsulatum spores are found or from clinical samples obtained from patients. Furthermore, the invention also provides for methods that detect the presence of H. capsulatum in a sample using a nested, or two-stage, PCR assay.
Commercial Applications
  • Directing antifungal drug therapy for improved patient outcomes
  • Occupational health and safety screening for workers who may encounter bird or bat waste
  • Screening biological or soil samples for the presence of fungal pathogens
  • Environment testing for immunocompromised patients
Competitive Advantages
  • Rapid and precise
  • Cost-effective
  • Easily adapted for H. capsulatum detection kits
  • Can positively identify small sample sizes of as few as 10 spores
  • High-throughput capable

Request More Info

Licensing Contact: